-
Next generation medicinesLearn moreWe design and develop drugs based on a novel therapeutic approach called melitherapy. -
A new pharmaceutical perspectiveLearn moreOur drugs are first-in-class molecules which target membrane lipids, instead of acting directly on proteins or DNA like other medicines.
-
Committed
to peopleLearn moreOur goal is to deliver reference treatments for illnesses with unmet medical needs, such as cancer and Alzheimer’s disease.
NEW SEEK CAPITAL ROUND OPEN UNTIL 15/08/2024!
We aim to finance Phase III clinical trials for brain tumor treatment.
For more information about this investment opportunity click here
email inversores@laminarpharma.com.
3 MILLION € ALREADY RAISED!
The latest LAMINAR PHARMA WEBINAR held on JUNE 11st 2024 is NOW AVAILABLE
Scientific publications
- Tri-2-Hydroxyarachidonein Induces Cytocidal Autophagy in Pancreatic Ductal Adenocarcinoma Cancer Cell Models
- Multifaceted Analyses of Isolated Mitochondria Establish the Anticancer Drug 2-Hydroxyoleic Acid as an Inhibitor of Substrate Oxidation and an Activator of Complex IV-Dependent State 3 Respiration.
- Lipids in Pathophysiology and Development of the Membrane Lipid Therapy: New Bioactive Lipids.